Advanced Proteome Therapeutics Corporation: Appointment of Chief Financial Officer
10 Marzo 2009 - 2:20PM
Marketwired
Advanced Proteome Therapeutics Corporation (the "Corporation") (TSX
VENTURE: APC) is pleased to announce that Kenneth C. Phillippe has
accepted the position of Chief Financial Officer of the
Corporation, effective immediately. Mr. Phillippe will assume the
position of Chief Financial Officer from Alexander (Allen) Krantz,
who has served as Chief Financial Officer since October 23, 2006.
Mr. Krantz will continue to act as President, Chief Executive
Officer and Secretary of the Corporation.
Mr. Phillippe is a Chartered Accountant with over 25 years
experience working with public companies in the capacities of
director, officer, financial advisor or consultant. He obtained a
Bachelor of Commerce degree from the University of British Columbia
in 1976 and his professional accounting designation in 1981. In the
past Mr. Phillippe has served as a director and officer of
Urodynamix Technologies Ltd., a Vancouver-based medical device
company; chief financial officer of Columbia Goldfields Ltd., a
junior gold mining company; Secretary, Treasurer, Chief Financial
Officer and Principal Accounting Officer of Amazon Goldsands Ltd.
and Constitution Mining Corp. Mr. Phillippe currently serves as
Chief Financial Officer of Exchequer Resource Corp. and Chief
Financial Officer and Secretary of Bold Ventures Inc.
Alexander Krantz, President, stated that "we are delighted to
have Ken Phillippe assume the role of CFO in light of his vast
accounting experience and expertise".
About APC
APC's primary corporate mission is to apply its proprietary drug
delivery and drug redevelopment technologies to produce new,
improved versions of therapeutic proteins and pioneer the emerging
field of protein-site targeting. The market for diagnostics and
therapeutic proteins and peptides is expected to surpass more than
50 Billion USD by the year 2010 and is the fastest growing segment
of the pharmaceutical market. Future growth however depends largely
on the industry overcoming a number of hurdles, including drug
delivery challenges and the need for homogeneous conjugates that
APC is attempting to address.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive
Officer
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Encompass Communications Inc. (604) 630-0770 or Toll
Free: 1-877-566-6592
Grafico Azioni Advanced Proteome Therap... (TSXV:APC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Advanced Proteome Therap... (TSXV:APC)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Advanced Proteome Therapeutics Corporation (Venture Exchange Canada (TSXV)): 0 articoli recenti
Più Advanced Proteome Therapeutics Corporation Articoli Notizie